林业发展局批准Vonvendi在成人和儿童中治疗所有类型的Vonvendi von Willebrand 病。 FDA approves Vonvendi for treating all types of von Willebrand disease in adults and children.

林业发展局已核准扩大使用Vonvendi,这是Takeda制药公司的一种药物,用于对患有Von Willebrand疾病(VWD)的成年人进行常规预防治疗,并用于管理怀有Vebrand病的儿童出血事件和手术。 The FDA has approved expanded use of Vonvendi, a drug by Takeda Pharmaceuticals, for routine preventative treatment in adults with von Willebrand disease (VWD) and for managing bleeding episodes and surgeries in children with VWD. 这使得Vonvendi成为美国所有各类维也纳妇女所批准的唯一非塑料衍生的VWF产品。 This makes Vonvendi the only non-plasma derived VWF product approved for all types of VWD in the US. 常见副作用包括头痛、呕吐、恶心、头晕和皮肤发痒。 Common side effects include headache, vomiting, nausea, dizziness, and itchy skin.